CAMBRIDGE, MA, AND PARIS, FRANCE, January 9, 2017 – In a paper published in Drug Discovery Today, HiFiBiO CEO Liang Schweizer and COO Jeff He describe a framework and outline principles to facilitate collaborative partnerships in drug discovery research.
The paper, “Guiding principles of value creation through collaborative innovation in pharmaceutical research” outlines the importance of breaking down common barriers in collaborations, proposes four guiding principles for such co-operation and offers a framework to reach value inflection points quicker.
Abstract of paper:
Open innovation has become the main trend in pharmaceutical research. Potential obstacles and pitfalls of collaborations often lead to missed opportunities and/or poorly executed partnerships. This paper aims to provide a framework that facilitates the execution of successful collaborations. We start by mapping out three checkpoints onto early-stage collaborative partnerships: inception, ignition and implementation. Different value types and value drivers are then laid out for each phase of the partnership. We proceed to propose a ratio-driven approach and a value-adjustment mechanism, enhancing the probability of successes in pharmaceutical research collaborations. These guiding principles combined should help the partners either reach agreement more quickly or move on to the next potential project.